Overview

BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This is a clinical study investigating pharmacokinetics, pharmacodynamic effects and safety of BAY 59-7939 in patients with atrial fibrillation (originally described in Japanese).
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Rivaroxaban